Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antifungal
Biotech
Pfizer cuts 3 assets as R&D spend drops 24% in Q4
Pfizer is discarding three assets—one of which was the heart of a 2021 Amplyx acquisition—after R&D spending dropped 24% in the Q4.
Gabrielle Masson
Jan 30, 2024 11:37am
Basilea continues pipeline refill with Pfizer antifungal
Nov 13, 2023 8:15am
Basilea anti-infective strategy restarts with $2M antifungal buy
Oct 19, 2023 7:25am
FDA stalls F2G's plans to get new class of antifungal to market
Jun 20, 2023 9:30am
Basilea hands back antifungal 9 months after licensing it
Jan 17, 2023 7:15am
Melinta pays Cidara $30M for antifungal pending FDA review
Jul 27, 2022 11:05am